|
|
|
Prospective research on the efficacy and safety of oxcarbazepine as monotherapy and add-on therapy for partial epilepsy |
Huicong KANG, Xiaoyan LIU, Hu QI, Feng XU, Xiang LI, Yuan WANG, Zhiguang LIU, Suiqiang ZHU( ) |
| Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China |
|
|
|
|
Abstract The purpose of our research was to evaluate the efficacy, tolerance, and safety of oxcarbazepine (OXC) as monotherapy and add-on therapy for partial epilepsy. We carried out a prospective clinical follow-up trial at the Epilepsy Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Sixty-seven patients with partial epilepsy received OXC therapy. The patients were randomly divided into a monotherapy group and an add-on therapy group. We observed the efficacy and safety in the first three months and the following three months respectively, and compared them with each other. There was a significant difference in the decrease of seizure frequency between the two groups (P = 0.002). There was a significant difference in the percentage of seizure-free between the monotherapy and the add-on therapy groups in the first three months (P = 0.02), and there were also statistical differences in the 50% response rate (P = 0.017) and the percentage of seizure-free in the following three months (P = 0.019). No difference was found in the 50% response rate, the 75% response rate, and the percentage of seizure-free between the first three months and the following three months in the whole group and the two subgroups (P > 0.05). The incidence rate of side effects due to the therapy was 19.40% (13 of 67). The side effects were mainly found in the first three months. It is concluded that OXC is the first-line anti-epileptic drug (AED) for partial seizures, and could be used as the monotherapy and add-on therapy for newly diagnosed patients and patients that failed to tolerate or benefit from other AEDs.
|
| Keywords
oxcarbazepine
partial epilepsy
|
|
Corresponding Author(s):
ZHU Suiqiang,Email:zhusuiqiang@163.com
|
|
Issue Date: 05 June 2009
|
|
| 1 |
Giustizieri M, Armogida M, Berretta N, Federici M, Piccirilli S, Mercuri N B, Nistico R. Differential effect of carbamazepine and oxcarbazepine on excitatory synaptic transmission in rat hippocampus. Synapse , 2008, 62(10): 783-789
doi: 10.1002/syn.20556
|
| 2 |
Ambrosio A F, Soares-Da-Silva P, Carvalho C M, Carvalho A P. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res , 2002, 27(1): 121-130
doi: 10.1023/A:1014814924965
|
| 3 |
Dogan E A, Usta B E, Bilgen R, Senol Y, Aktekin B. Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy. Epilepsy Behav , 2008, 13(1): 156-161
doi: 10.1016/j.yebeh.2008.02.001
|
| 4 |
Gazzola D M, Balcer L J, French J A. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia , 2007, 48(7): 1303-1307
doi: 10.1111/j.1528-1167.2007.01136.x
|
| 5 |
Marson A G, Appleton R, Baker G A, Chadwick D W, Doughty J, Eaton B, Gamble C, Jacoby A, Shackley P, Smith D F, Tudur-Smith C, Vanoli A, Williamson P R. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technol Assess , 2007, 11(37): iii-iv, ix-x, 1-134
|
| 6 |
Herranz J L, Argumosa A, Salas-Puig J. Oxcarbazepine in monotherapy in 324 patients with partial seizures (TRINOVA study). Rev Neurol , 2004, 39(7): 601-606
|
| 7 |
French J A, Kanner A M, Bautista J, Abou-Khalil B, Browne T, Harden C L, Theodore W H, Bazil C, Stern J, Schachter S C, Bergen D, Hirtz D, Montouris G D, Nespeca M, Gidal B, Marks W J Jr, Turk W R, Fischer J H, Bourgeois B, Wilner A, Faught R E Jr, Sachdeo R C, Beydoun A, Glauser T A. Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia , 2004, 45(5): 401-409
|
| 8 |
French J A, Kanner A M, Bautista J, Abou-Khalil B, Browne T, Harden C L, Theodore W H, Bazil C, Stern J, Schachter S C, Bergen D, Hirtz D, Montouris G D, Nespeca M, Gidal B, Marks W J Jr, Turk W R, Fischer J H, Bourgeois B, Wilner A, Faught R E Jr, Sachdeo R C, Beydoun A, Glauser T A. Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia , 2004, 45(5): 410-423
doi: 10.1111/j.0013-9580.2004.06304.x
|
| 9 |
Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, Kalviainen R, Mattson R, Perucca E, Tomson T. ILAE treatment guidelines: Evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia , 2006, 47(7): 1094-1120
doi: 10.1111/j.1528-1167.2006.00585.x
|
| 10 |
Freidel M, Krause E, Kuhn K, Peper R, Vogel H. Oxcarbazepine in the treatment of epilepsy, 2007, 75(2): 100-106
|
| 11 |
Pauletto G, Bergonzi P; Triveneto Epilepsy Study Group. Oxcarbazepine reduces seizure frequency in a high proportion of patients with both newly diagnosed and refractory partial seizures in clinical practice. Seizure , 2006, 15(3): 150-155
doi: 10.1016/j.seizure.2005.12.008
|
| 12 |
Beydoun A, Sachdeo R C, Kutluay E, McCague K, D'Souza J. Sustained efficacy and long-term safety of oxcarbazepine: one-year open-label extension of a study in refractory partial epilepsy. Epilepsia , 2003, 44(9): 1160-1165
doi: 10.1046/j.1528-1157.2003.54102.x
|
| 13 |
Schmidt D, Arroyo S, Baulac M, Dam M, Dulac O, Friis M L, K?lvi?inen R, Kr?mer G, van Parys J, Pedersen B, Sachdeo R. Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy:a consensus view. Acta Neurol Scand , 2001, 104: 167-170
doi: 10.1034/j.1600-0404.2001.00870.x
|
| 14 |
Schmidt D, Sachdeo R. Oxcarbazepine for treatment of partial epilepsy: A review and recommendations for clinical use. Epilepsy Behav , 2000, 1(6): 396-405
doi: 10.1006/ebeh.2000.0126
|
| 15 |
Freidel M, Krause E, Kuhn K, Peper R, Vogel H. Oxcarbazepine in the treatment of epilepsy. Fortschr Neurol Psychiatr , 2007, 75(2): 100-106
|
| 16 |
Zaccara G, Messori A, Cincotta M, Burchini G. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand , 2006, 114(3): 157-168
doi: 10.1111/j.1600-0404.2006.00705.x
|
| 17 |
Franzoni E, Garone C, Sarajlija J, Gualandi S, Malaspina E, Cecconi I, Moscano F C, Marchiani V. Open prospective study on oxcarbazepine in epilepsy in children: a preliminary report. Seizure , 2006, 15(5): 292-298
doi: 10.1016/j.seizure.2006.02.017
|
| 18 |
Novartis. Oxcarbazepine. Data on file, Basle , 1998
|
| 19 |
Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess , 2005, 9(15): 1-157
|
| 20 |
Aldenkamp A P, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia , 2003, 44(Suppl 4): 21-29
doi: 10.1046/j.1528-1157.44.s4.3.x
|
| 21 |
Beydoun A, Sachdeo R C, Rosenfeld W E, Krauss G L, Sessler N, Mesenbrink P, Kramer L, D'Souza J. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology , 2000, 54(12): 2245-2251
|
| 22 |
Kraiprab P, Chinvarun Y, Tantisira M H. Oxcarbazepine as add-on therapy in Thai epileptic patients with refractory partial seizures. J Med Assoc Thai , 2005, 88(Suppl 3): S193-201
|
| 23 |
Patsalos P N, Berry D J, Bourgeois B F, Cloyd J C, Glauser T A, Johannessen S I, Leppik I E, Tomson T, Perucca E. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia , 2008, 49(7): 1239-1276
doi: 10.1111/j.1528-1167.2008.01561.x
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
